Study of VIR-2482 in Healthy Volunteers

Vir Biotechnology

Status and phase: Completed; Phase 1

Conditions: Influenza A

Treatments: Drug: Placebo; Drug: VIR-2482

Study type: Interventional

Funder types: Industry

Identifiers

NCT04033406

VIR-2482-3001

Details and patient eligibility

About

This is a phase 1 study in which healthy volunteers will receive VIR-2482 or placebo and will be assessed for safety, pharmacokinetics, and immunogenicity of VIR-2482 in preventing Influenza A illness.

Enrollment: 100 patients

Sex: All

Ages: 18 to 64 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy Male or Female age 18 to < 65 years
• Body mass index (BMI) of 18.0 kg/m^2 to 32.0kg/m^2

Exclusion criteria

• Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation
• History of influenza-like illness or confirmed influenza infection within 3 months prior to randomization.
• Fever-like illness within 5 days of randomization.
• History or clinical evidence of conditions considered high risk for developing influenza-related complications.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

100 participants in 2 patient groups, including a placebo group

VIR-2482

Experimental group

Description:

VIR-2482

Treatment:

Drug: VIR-2482

Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo